One novel and two recurrent THRB mutations associated with resistance to thyroid hormone

Structure-based computational mutation prediction

Satoshi Narumi, Hideo Cho, Izumi Tamada, Yuki Kozu, Takayoshi Tsuchiya, Toshiro Nagai, Tomonobu Hasegawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Inactivating mutations of THRB, which encodes the thyroid hormone receptor β (TRβ), cause resistance to thyroid hormone (RTH; OMIM 190160). To date, more than 100 THRB mutations have been reported among RTH patients. Most mutations substitute a single amino-acid residue in the ligand-binding domain. In this report, we describe clinical and molecular findings of three families with RTH. Three families harbored one novel (p.I431M) and two recurrent (p.R320H and p.R383C) THRB mutations. To examine the pathogenicity of identified mutations, we introduced a novel computational mutation prediction method based on three-dimensional structure data of TRβ-T3 complex. First, to define the accuracy of our prediction system, we evaluated ten previously reported 'positive control' mutations, as well as 30 seemingly benign sequence variations observed among vertebral species as 'negative controls'. We found that our system had a sensitivity of 80% and a specificity of 93%. We then analyzed three mutations detected in the present study and found that all three mutations are predicted to be deleterious. Our data suggest that our structure-based prediction system would be a prompt, inexpensive and feasible method for evaluating the pathogenicity of missense THRB mutations.

Original languageEnglish
Pages (from-to)91-99
Number of pages9
JournalClinical Pediatric Endocrinology
Volume19
Issue number4
DOIs
Publication statusPublished - 2010

Fingerprint

Thyroid Hormone Resistance Syndrome
Mutation
Thyroid Hormone Receptors
Virulence
CD3 Antigens
Genetic Databases
Missense Mutation

Keywords

  • Computational biology
  • Genetics
  • Mutation
  • Thyroid hormone receptor beta
  • Thyroid hormone resistance syndrome

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Pediatrics, Perinatology, and Child Health

Cite this

One novel and two recurrent THRB mutations associated with resistance to thyroid hormone : Structure-based computational mutation prediction. / Narumi, Satoshi; Cho, Hideo; Tamada, Izumi; Kozu, Yuki; Tsuchiya, Takayoshi; Nagai, Toshiro; Hasegawa, Tomonobu.

In: Clinical Pediatric Endocrinology, Vol. 19, No. 4, 2010, p. 91-99.

Research output: Contribution to journalArticle

Narumi, Satoshi ; Cho, Hideo ; Tamada, Izumi ; Kozu, Yuki ; Tsuchiya, Takayoshi ; Nagai, Toshiro ; Hasegawa, Tomonobu. / One novel and two recurrent THRB mutations associated with resistance to thyroid hormone : Structure-based computational mutation prediction. In: Clinical Pediatric Endocrinology. 2010 ; Vol. 19, No. 4. pp. 91-99.
@article{465bb0f735ea4789a2f9ebdfde4b6d99,
title = "One novel and two recurrent THRB mutations associated with resistance to thyroid hormone: Structure-based computational mutation prediction",
abstract = "Inactivating mutations of THRB, which encodes the thyroid hormone receptor β (TRβ), cause resistance to thyroid hormone (RTH; OMIM 190160). To date, more than 100 THRB mutations have been reported among RTH patients. Most mutations substitute a single amino-acid residue in the ligand-binding domain. In this report, we describe clinical and molecular findings of three families with RTH. Three families harbored one novel (p.I431M) and two recurrent (p.R320H and p.R383C) THRB mutations. To examine the pathogenicity of identified mutations, we introduced a novel computational mutation prediction method based on three-dimensional structure data of TRβ-T3 complex. First, to define the accuracy of our prediction system, we evaluated ten previously reported 'positive control' mutations, as well as 30 seemingly benign sequence variations observed among vertebral species as 'negative controls'. We found that our system had a sensitivity of 80{\%} and a specificity of 93{\%}. We then analyzed three mutations detected in the present study and found that all three mutations are predicted to be deleterious. Our data suggest that our structure-based prediction system would be a prompt, inexpensive and feasible method for evaluating the pathogenicity of missense THRB mutations.",
keywords = "Computational biology, Genetics, Mutation, Thyroid hormone receptor beta, Thyroid hormone resistance syndrome",
author = "Satoshi Narumi and Hideo Cho and Izumi Tamada and Yuki Kozu and Takayoshi Tsuchiya and Toshiro Nagai and Tomonobu Hasegawa",
year = "2010",
doi = "10.1297/cpe.19.91",
language = "English",
volume = "19",
pages = "91--99",
journal = "Clinical Pediatric Endocrinology",
issn = "0918-5739",
publisher = "Jeff Corporation Co. Ltd",
number = "4",

}

TY - JOUR

T1 - One novel and two recurrent THRB mutations associated with resistance to thyroid hormone

T2 - Structure-based computational mutation prediction

AU - Narumi, Satoshi

AU - Cho, Hideo

AU - Tamada, Izumi

AU - Kozu, Yuki

AU - Tsuchiya, Takayoshi

AU - Nagai, Toshiro

AU - Hasegawa, Tomonobu

PY - 2010

Y1 - 2010

N2 - Inactivating mutations of THRB, which encodes the thyroid hormone receptor β (TRβ), cause resistance to thyroid hormone (RTH; OMIM 190160). To date, more than 100 THRB mutations have been reported among RTH patients. Most mutations substitute a single amino-acid residue in the ligand-binding domain. In this report, we describe clinical and molecular findings of three families with RTH. Three families harbored one novel (p.I431M) and two recurrent (p.R320H and p.R383C) THRB mutations. To examine the pathogenicity of identified mutations, we introduced a novel computational mutation prediction method based on three-dimensional structure data of TRβ-T3 complex. First, to define the accuracy of our prediction system, we evaluated ten previously reported 'positive control' mutations, as well as 30 seemingly benign sequence variations observed among vertebral species as 'negative controls'. We found that our system had a sensitivity of 80% and a specificity of 93%. We then analyzed three mutations detected in the present study and found that all three mutations are predicted to be deleterious. Our data suggest that our structure-based prediction system would be a prompt, inexpensive and feasible method for evaluating the pathogenicity of missense THRB mutations.

AB - Inactivating mutations of THRB, which encodes the thyroid hormone receptor β (TRβ), cause resistance to thyroid hormone (RTH; OMIM 190160). To date, more than 100 THRB mutations have been reported among RTH patients. Most mutations substitute a single amino-acid residue in the ligand-binding domain. In this report, we describe clinical and molecular findings of three families with RTH. Three families harbored one novel (p.I431M) and two recurrent (p.R320H and p.R383C) THRB mutations. To examine the pathogenicity of identified mutations, we introduced a novel computational mutation prediction method based on three-dimensional structure data of TRβ-T3 complex. First, to define the accuracy of our prediction system, we evaluated ten previously reported 'positive control' mutations, as well as 30 seemingly benign sequence variations observed among vertebral species as 'negative controls'. We found that our system had a sensitivity of 80% and a specificity of 93%. We then analyzed three mutations detected in the present study and found that all three mutations are predicted to be deleterious. Our data suggest that our structure-based prediction system would be a prompt, inexpensive and feasible method for evaluating the pathogenicity of missense THRB mutations.

KW - Computational biology

KW - Genetics

KW - Mutation

KW - Thyroid hormone receptor beta

KW - Thyroid hormone resistance syndrome

UR - http://www.scopus.com/inward/record.url?scp=78651399789&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651399789&partnerID=8YFLogxK

U2 - 10.1297/cpe.19.91

DO - 10.1297/cpe.19.91

M3 - Article

VL - 19

SP - 91

EP - 99

JO - Clinical Pediatric Endocrinology

JF - Clinical Pediatric Endocrinology

SN - 0918-5739

IS - 4

ER -